Active Biofeedback for Major Depressive Disorder (MDD)

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Major Depressive Disorder (MDD)+2 More
Active Biofeedback - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether VTA self-modulation with biofeedback can improve depression symptoms in humans.

Eligible Conditions
  • Major Depressive Disorder (MDD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: baseline (Pre-training) and 2 hours (Post-training) during the assessment visit

Hour 2
Percent Increase in VTA Activation during MOTIVATE trials

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Active Biofeedback
1 of 2
Sham Biofeedback
1 of 2

Experimental Treatment

Non-Treatment Group

60 Total Participants · 2 Treatment Groups

Primary Treatment: Active Biofeedback · Has Placebo Group · N/A

Active Biofeedback
Behavioral
Experimental Group · 1 Intervention: Active Biofeedback · Intervention Types: Behavioral
Sham Biofeedback
Behavioral
ShamComparator Group · 1 Intervention: Sham Biofeedback · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline (pre-training) and 2 hours (post-training) during the assessment visit

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiLead Sponsor
774 Previous Clinical Trials
482,691 Total Patients Enrolled
11 Trials studying Major Depressive Disorder (MDD)
481 Patients Enrolled for Major Depressive Disorder (MDD)
Laurel Morris, PhDPrincipal Investigator - Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be able to understand and agree to the study and examination requirements.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 8th, 2021

Last Reviewed: November 26th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

Who else is applying?

What state do they live in?
New York100.0%
How old are they?
18 - 65100.0%
What site did they apply to?
Icahn School of Medicine at Mount Sinai100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%

How responsive is this trial?

Most responsive sites:
  1. Icahn School of Medicine at Mount Sinai: < 24 hours
Average response time
  • < 1 Day
Typically responds via
Phone Call50.0%
Email50.0%